Abbott’s 3Q $8.9Bn Sales Beat Wall Street Consensus, Medtech Sales Up 3.4%

Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.

Business growth

Abbott ’s reported third-quarter 2020 global sales of $8.9bn beat Wall Street estimates by $314m, driven by its strong position in COVID-19 tests, which reached $881m in sales this quarter, and a strong return in medtech sales, particularly in diabetes care.

After a tough second quarter, the company’s third-quarter sales rose 9.6% from $8.07bn in the third quarter a year ago,...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Financing

More from Business